Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 964 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Completed Phase 2 Interventional

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

NCT00630227
View directory record Official record
Conditions
Homogeneous Emphysema
Interventions
Biologic Lung Volume Reduction
Biological
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional

A Trial to Reduce Readmissions Using Motivational Interviewing and Interactive Voice Response

NCT01855022
View directory record Official record
Conditions
Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
MI + IVR
Behavioral
Lead sponsor
Asante Health System
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Grants Pass, Oregon • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Respiratory Disease Management

NCT01543217
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
RT management, Ususal care
Other
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD

NCT01108991
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Physical activity self-management, COPD education + Usual care
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
45 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

NCT05158387
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
34
States / cities
Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 13, 2026, 3:52 PM EDT
Not listed Not applicable Interventional

Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients

NCT03531489
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
AIR-AD
Device
Lead sponsor
Right-Air
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 13, 2026, 3:52 PM EDT
Completed No phase listed Observational

Investigating the Impact of Mode of Administration on Item Response

NCT00783991
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Palo Alto, California • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00510510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NVA237 100 µg, Placebo, NVA237 200 µg
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phoenix, Arizona • Wheat Ridge, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 13, 2026, 3:52 PM EDT
Recruiting No phase listed Observational

Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study

NCT01177618
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 13, 2026, 3:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations

NCT00774176
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
1,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

NCT02867761
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Indacaterol/Glycopyrrolate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional Results available

Uphill Walking as Exercise for COPD Patients

NCT04026529
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
walking on incline or walking at increasing speed
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02518139
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Tiotropium
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

NCT05492877
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Mitiperstat (AZD4831), Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Clearwater, Florida • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Work Intervention Focused on Transitions

NCT02232126
View directory record Official record
Conditions
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension, Cancer, Depression, Asthma, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Stroke
Interventions
SWIFT home intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 110 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 13, 2026, 3:52 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant

NCT03111888
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
Silicone Stent Airway Implant
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 13, 2026, 3:52 PM EDT
Withdrawn Phase 4 Interventional

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

NCT03949842
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 13, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03256695
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol sulfate (ABS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 13, 2026, 3:52 PM EDT